Proton pump inhibitors with histamine 2 receptor antagonists have been shown to reduce all-cause mortality in patients with systemic sclerosis and interstitial lung disease. Combination therapy was found to be more effective than single-agent treatment in improving survival. A study conducted by Alannah Quinlivan and colleagues analyzed data from the Australian Scleroderma Cohort Study, including 1,632 patients with systemic sclerosis, 29% of whom had interstitial lung disease. While there was no direct relationship between gastroesophageal reflux disease and ILD severity, treatment with PPI and H2RA was associated with improved survival, highlighting the benefits of anti-reflux therapy in these patients.
Source link
‘Aggressive’ treatment of GERD improves survival in systemic sclerosis with ILD
